Publications by authors named "Elizabeth Misener"

Claim this Profile
P
Problem-solving therapy for late-life depression in home care: a randomized field trial.
Zvi D Gellis, Jean McGinty, Amy Horowitz, Martha L Bruce, Elizabeth Misener

Am J Geriatr Psychiatry· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
James R Henry, Yihong Li, Alan M Warshawsky, Joseph T Brozinick, Eric D Hawkins, Elizabeth A Misener

Bioorg Med Chem Lett· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.
Alan M Warshawsky, Charles A Alt, Joseph T Brozinick, Allen R Harkness, Eric D Hawkins, Elizabeth A Misener

Bioorg Med Chem Lett· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of potent and selective bisarylmaleimide GSK3 inhibitors.
Thomas A Engler, Sushant Malhotra, Timothy P Burkholder, James R Henry, David Mendel, Elizabeth Misener

Bioorg Med Chem Lett· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
José A Martín, Dawn A Brooks, Lourdes Prieto, Rosario González, Alicia Torrado, Elizabeth A Misener

Bioorg Med Chem Lett· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Thomas A Engler, James R Henry, Sushant Malhotra, Brian Cunningham, Kelly Furness, Elizabeth Misener

J Med Chem· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Garret J Etgen, Brian A Oldham, William T Johnson, Carol L Broderick, Chahrzad R Montrose, Elizabeth A Misener

Diabetes· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis